The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.
Generic medicines can cost up to 30 times more in poor countries, according to a new study.
India is to make barcoding mandatory on all medicines sold within the country after a recent report by the Office of the US Trade Representative (USTR) identified the country as the largest producer of counterfeit pharmaceuticals in the world.
A German court has rejected a bid from French pharmaceutical company Sanofi to have a patent infringement case dismissed.
A Japanese court has dismissed a patent infringement lawsuit brought by Roche subsidiary Genentech against Sandoz, a division of Novartis.
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.
The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.
Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.